Navigation Links
AEterna Zentaris Reports Fourth Quarter and Full-Year 2008 Financial and Operating Results
Date:3/11/2009

All amounts are in U.S. dollars

QUEBEC CITY, March 11 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) ("the Company"), a global biopharmaceutical company focused on endocrinology and oncology, today reported financial and operating results for the fourth quarter and the full year ended December 31, 2008.

    2008 Highlights

    - February

      - First patients treated with AEZS-108 for a Phase 2 trial in advanced
        ovarian and endometrial cancers.

    - March

      - Patient dosing commenced with cetrorelix in the second efficacy study
        of the Phase 3 program in benign prostatic hyperplasia ("BPH").
      - Completion of the sale to Paladin Labs of the marketed product,
        Impavido(R) (miltefosine), for approximately $9.2 million.

    - April

      - Appointment of Juergen Ernst, as Interim President and CEO, the
        Company's Chairman of the Board at the time, following the departure
        of our former President and CEO;
      - Completion of patient recruitment for the first efficacy study of the
        Phase 3 program in BPH with cetrorelix.

    - May

      - First patients treated with cetrorelix for the safety trial of the
        Phase 3 program in BPH.

    - June

      - Completion of the sale of the Company's Quebec City property for a
        purchase price of $7.1 million.

    - September

      - Appointment of Juergen Engel, Ph.D., as Company President and CEO,
        succeeding Juergen Ernst who, at the same time, was appointed as
        Executive Chairman of the Company.

    - October and November

      - Completion of patient recruitment for the second efficacy trial of
        the Phase 3 program with cetrorelix in BPH.

      - Initiation of the second stage of patient recruitment for AEZS-108
        P
'/>"/>
SOURCE  AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
3. AEterna Zentaris Announces Outcome of Managements Strategic Review
4. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
5. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
6. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
7. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
8. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
9. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
10. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
11. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... (PRWEB) May 17, 2013 Rust removal is ... and non-metal home items could be damaged. To help rust ... use of its no-scrubbing rust remover it called ... able available with 10% discount. , My Cleaning Products explained ... corroding them or by staining them. The first one, ...
(Date:5/16/2013)... 16, 2013 ISPE ... Myers, CAE, to the newly created position of ... role, Myers will be responsible for stimulating ISPE’s ... strategies, advancing the Society’s Member-led and staff-driven business ... to refine organizational, membership and product marketing. , ...
(Date:5/16/2013)... May 16, 2013 Cambridge Healthtech Institute ... August 19-23, 2013 at the Renaissance Waterfront Hotel in ... provide a close-up look at the current strategies and ... bottom-line quality. Leaders in the field will reveal ... produce biopharmaceuticals with greater specificity and efficiency. , “In ...
(Date:5/16/2013)... 16, 2013 Scientists at the Center for ... , and the California -based biopharmaceutical ... novel therapy for reversing memory decline in mice with ... significant cognitive improvement in advanced stage AD mice. The ... reversing cognitive decline for advanced stage AD mice, and ...
Breaking Biology Technology:Organic-Based Rust Remover Cuts Down Price by 10%, My Cleaning Products Details Mechanics How to Get the Discount 2ISPE Names Barbara A. Myers, CAE, as Vice President of Professional Development 2The 2013 Bioprocessing Summit to Bring Together International Leaders to Discuss Today's Bioprocess Issues From Cell Line Selection to Manufacturing in Boston, MA 2Elevation of Brain Magnesium Reverses Memory Deficits in Alzheimer Mice 2Elevation of Brain Magnesium Reverses Memory Deficits in Alzheimer Mice 3
... Excellence and Patient Ease-of-Use, BROOKFIELD, Wis., April ... won the 2008 Medical Design Excellence Awards (MDEA) ... Genesis DM won in the,rehabilitation and assistive-technology products ... monitoring device is,ideal for both the patient and ...
... Replikins Ltd. has found that the,Replikin Count(TM) of the ... (plus/minus 1.4), its highest level since the 1918 H1N1,pandemic ... of a particular,influenza strain, indicating rapid replication of the ... by an outbreak of the specific,strain. The current increase ...
... 2008 A,cross-disciplinary research team at the University of ... drug research platform can,produce the chemical reactions needed to ... on a tiny "biochip" created to mimic,the environment within ... This means that the researchers can proceed to the ...
Cached Biology Technology:Honeywell HomMed Wins 2008 Medical Design Excellence Award for Genesis DM Remote Care Device 2Honeywell HomMed Wins 2008 Medical Design Excellence Award for Genesis DM Remote Care Device 3H1N1 Influenza Virus With Highest Replikin Count(TM) Since the 1918 Pandemic Identified in the U.S. and Austria 2U-Md. Researchers Report Advance in Biological Microfactories for Drug Research 2U-Md. Researchers Report Advance in Biological Microfactories for Drug Research 3U-Md. Researchers Report Advance in Biological Microfactories for Drug Research 4
(Date:5/17/2013)... of all ages will celebrate the science and ... our daily lives during the inaugural Atlanta Science ... educators from local museums, corporations, K-12 schools and ... different events for children and adults at venues ... . , The annual Atlanta Science Festival ...
(Date:5/17/2013)... of American Societies for Experimental Biology (FASEB) released a ... (NIH) funding trends highlighting the devastating impact of sequestration ... FASEB analysis follows a May 15th Senate Appropriations Committee ... testified that the $1.6 billion cut the agency sustained ... substantial impact on the scientific community." , According ...
(Date:5/16/2013)... to a fast food restaurant had a higher body ... from fast food, according to researchers at The University ... was particularly strong among those with a lower income. ... American Journal of Public Health indicates higher ... restaurant, and among lower-income African-Americans, the density, or number, ...
Breaking Biology News(10 mins):First Atlanta Science Festival set for 2014 2Body mass index of low income African-Americans linked to proximity of fast food restaurants 2Body mass index of low income African-Americans linked to proximity of fast food restaurants 3
... famed starship Enterprise would deploy a deflector shield to evade ... molecular force field of their own to fend off treatments ... found a chink in their armor. , The cells churn ... protective barrier that deflects damage from radiation or chemotherapy and ...
... study of more than 68,000 infants published in this ... Rotateq demonstrated that it can safely prevent 98 percent ... account for 2 million hospital visits and 500,000 pediatric ... largest pre-licensure vaccine clinical trials ever conducted worldwide, research ...
... the University of Pennsylvania, demonstrate that biodegradable nano-particles ... killing human breast tumors. The unique properties ... allow them to deliver two distinct drugs, paclitaxel, ... such as Taxol, and doxorubicin directly to tumors ...
Cached Biology News:Molecular force field helps cancer cells defend against attack 2Molecular force field helps cancer cells defend against attack 3New vaccine for condition that kills 500,000 children a year 2New vaccine for condition that kills 500,000 children a year 3Nano-particles effective in killing cancer with one-two punch of chemotherapeutics 2
Rat polyclonal to acetyl Salicylic Acid ( Abpromise for all tested applications)....
Rabbit polyclonal to UBC12 (rating: ****) ( Abpromise for all tested applications). Antigen: Synthetic peptide: RGGYIGSTYFER, corresponding to amino acids 169-180 of UBC12 Entrez Gene ID: 90...
...
... Product Mouse monoclonal [SPM278] to ... Small cell lung carcinoma N592 live cells ... with Human. Not yet tested in other ... of the major glycoproteins of basement membrane, ...
Biology Products: